- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00161954
Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
May 20, 2015 updated by: Pfizer
Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
The objective of this study is to establish the earliest time point at which vaccines are expected to show seropositive antibody levels after vaccination with FSME-IMMUN 0.5 mL using a rapid immunization schedule (2 vaccinations administered 12 +/- 2 days apart.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Antwerp, Belgium, 2060
- SGS Biopharma Research Unit Stuivenberg
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 65 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Understanding the nature of the study, agreement to its provisions and written informed consent
- Written informed consent of subject´s parents / legal guardians (if subject is under 18 years of age)
- Aged >= 16 years (from the 16th birthday) to <= 65 years (to the last day before the 66th birthday)
- Clinically healthy, (i. e. the physician would have no reservations vaccinating with FSME-IMMUN 0.5 ml outside the scope of a clinical trial)
- Negative pregnancy test result at the first medical examination (if female and capable of bearing children)
- Agreeing to employ adequate birth control measures for the duration of the study (if female and capable of bearing children)
- Agreeing to keep a subject diary.
Exclusion Criteria:
- History of any previous TBE vaccination
- History of TBE infection
- History of infection with other flaviviruses
- History of vaccination against yellow fever and/or Japanese B-encephalitis
- History of allergic reactions, in particular to one of the components of the vaccine
- Suffering from a disease (e.g. autoimmune disease) or undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions
- Known or suspected problem with drug or alcohol abuse (> 4 liters wine / week or equivalent level of other alcoholic beverages)
- Donation of blood or plasma within one month of study start
- Having received a blood transfusion or immunoglobulins within one month of study entry
- HIV positivity (an HIV test is not required specifically for the purpose of this study
- Simultaneous participation in another clinical trial including administration of an investigational product
- Participating in any other clinical study within six weeks prior to study start
- Participated in another Baxter vaccine study within the last six months (with the exception of follow-up studies)
- Pregnancy or lactation (if female)
- Having received any other vaccination within two weeks prior to study entry
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2004
Study Completion
May 1, 2004
Study Registration Dates
First Submitted
September 8, 2005
First Submitted That Met QC Criteria
September 12, 2005
First Posted (Estimate)
September 13, 2005
Study Record Updates
Last Update Posted (Estimate)
May 21, 2015
Last Update Submitted That Met QC Criteria
May 20, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Encephalitis, Arbovirus
- Encephalitis, Viral
- Central Nervous System Viral Diseases
- Central Nervous System Infections
- Infectious Encephalitis
- Arbovirus Infections
- Vector Borne Diseases
- Flavivirus Infections
- Flaviviridae Infections
- Tick-Borne Diseases
- Encephalitis
- Encephalitis, Tick-Borne
Other Study ID Numbers
- 225
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.